Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glükogeeni ladustamise ii tüüpi haigused - muud alimentary seedetrakti ja ainevahetust tooted, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastilised ained - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vaktsiinid - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ja 5. 1 in product information document). kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaktsiinid - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Euroopa Liit - eesti - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glükogeeni ladustamise ii tüüpi haigused - muud alimentary seedetrakti ja ainevahetust tooted, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Euroopa Liit - eesti - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaktsiinid - active immunisation against h5 subtype of influenza a virus.

Eesti - eesti - Ravimiamet

laboratorios liconsa s.a. - imatiniib - õhukese polümeerikattega tablett - 300mg 4tk; 300mg 24tk; 300mg 28tk; 300mg 60tk; 300mg 120tk; 300mg 90tk; 300mg 20tk; 300mg 1tk

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - montelukast - närimistablett - 5mg 84tk; 5mg 28tk; 5mg 30tk; 5mg 140tk; 5mg 7tk; 5mg 50tk; 5mg 90tk; 5mg 14tk

Eesti - eesti - Ravimiamet

fairmed healthcare gmbh - montelukast - närimistablett - 4mg 28tk; 4mg 50tk; 4mg 56tk; 4mg 200tk; 4mg 10tk; 4mg 20tk; 4mg 14tk; 4mg 7tk; 4mg 100tk